Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Reldesemtiv · CK-2127107

Small molecule · developed by Cytokinetics

Phase 3 Most advanced trial (none active)

CYTK Developer

2 Registered trials

What is Reldesemtiv?

Reldesemtiv is a small-molecule compound formulated as granules for oral suspension. It is studied in spinal muscular atrophy and amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CK-2127107
Drug type: Small molecule
Therapy area: Neurology
Developer: Cytokinetics (CYTK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 4S0HBYW6QE

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04944784	Phase 3	Amyotrophic Lateral Sclerosis	Terminated	CYTK
NCT02644668	Phase 2	Spinal Muscular Atrophy	Completed	CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral SclerosisSpinal Muscular Atrophy

More from Cytokinetics

Aficamten FDA approved AMG 423 Phase 1 CK-3828136 Phase 1 Omecamtiv Mecarbil Phase 3 SB-743921 Phase 1/2 Tirasemtiv Phase 3 Ulacamten Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CYTK page.

Follow CYTK, the company behind Reldesemtiv

See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CYTK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z